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ABSTRACT  24 
Recently, we have shown that the secretome of pancreatic cancer stem cells (CSCs) is characterized by 25 
proteins that participate in cancer differentiation, invasion, and metastasis. However, the differentially 26 
expressed intracellular proteins that lead to the specific characteristics of pancreatic CSCs have not yet 27 
been identified, and as a consequence the deranged metabolic pathways are yet to be elucidated. 28 
To identify the modulated proteins of pancreatic CSCs, iTRAQ-based proteomic analysis was 29 
performed to compare the proteome of Panc1 CSCs and Panc1 parental cells, identifying 230 30 
modulated proteins. Pathway analysis revealed activation of glycolysis, the pentose phosphate 31 
pathway, the pyruvate-malate cycle, and lipid metabolism as well as downregulation of the Krebs 32 
cycle, the splicesome and non-homologous end joining. These findings were supported by 33 
metabolomics and immunoblotting analysis. It was also found that inhibition of fatty acid synthase by 34 
cerulenin and of mevalonate pathways by atorvastatin have a greater anti-proliferative effect on cancer 35 
stem cells than parental cells.  36 
Taken together, these results clarify some important aspects of the metabolic network signature of 37 
pancreatic cancer stem cells, shedding light on key and novel therapeutic targets and suggesting that 38 
fatty acid synthesis and mevalonate pathways play a key role in ensuring their viability.  39 
 40 
 41 
  42 
 
 
Introduction 43 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive solid tumours with a 44 
mortality projected to surpass that of breast and colorectal cancer by 2030 in the United States [1]. 45 
More than 85% of patients who undergo surgical resection of small pancreatic tumours with clear 46 
surgical margins and no evidence of metastasis, die from metastasis within 5 years [2, 3], a finding that 47 
is consistent with early spread. Standard chemo- and radiation therapies, as well as new treatments 48 
targeting known oncogenes or growth factors, do not offer significant improvement of survival [4]. In 49 
line with these clinical observations, in a mouse model of PDAC, cellular dissemination leading to 50 
liver metastasis has been demonstrated to occur prior to the formation of an identifiable primary 51 
tumour. In addition, these circulating pancreatic cells have been shown to exhibit a mesenchymal 52 
phenotype and the expression of typical markers of cancer stem cells (CSCs). The CSC theory of 53 
cancer development is now generally accepted to explain the cellular heterogeneity observed within a 54 
tumour. Following this paradigm, only small subpopulations of the tumour cells, the CSCs, are capable 55 
to self renew, to give rise to a tumour and to recapitulate its heterogeneity by residing at the top of the 56 
cellular hierarchy. CSCs potentially explain several phenomena of cancer such as minimal residual 57 
disease, resistance to chemo- and radiation therapies, cancer recurrence and metastases [5]. Stem cells 58 
from several cancers, both liquid and solid, including PDAC, have been identified and shown to be 59 
particularly resistant to a broad spectrum of anticancer drugs [6]. The existence of CSCs has attractive 60 
prospective for identification of CSC-targeted therapies through the determination of the crucial 61 
molecules regulating the unique CSC properties. However, despite the enormous potential of CSCs as 62 
a new diagnostic and therapeutic target for human cancers, the specific molecular features of these 63 
cells are still far to be clarified mainly because of the difficulty to isolate sufficient amount of CSCs 64 
from tissue samples. Recently, cancer cell lines have been shown to be an alternative source for CSC 65 
research. Along these lines, our group has been able to isolate cancer stem-like cells from five out of 66 
nine PDAC cell lines [7] and has demonstrated that Panc1 CSCs showed the highest tumoursphere-67 
forming ability and were the most resistant to the action of various anticancer drugs. In order to deepen 68 
 
 
the knowledge of the specific molecular features of these cells, a proteomic approach has then been 69 
chosen [8]. In particular, the secretome analysis of Panc1 CSCs has identified a total of 43 proteins 70 
secreted at higher level by pancreatic CSCs compared to the parental cell line [9]. These data, together 71 
with ELISA assays performed on sera of PDAC patients, has suggested that at least one of the highly 72 
secreted proteins by CSCs, i.e. ceruloplasmin, is a promising marker for patients negative for CA19-9 73 
[9]. 74 
Here, we report the proteomic analysis of the intracellular proteins of Panc1 CSCs and parental 75 
cells. We show that in Panc1 CSCs 115 proteins were up-regulated and 115 down-regulated as 76 
compared to parental cells. In silico functional pathway analysis and network reconstruction based on 77 
signalling reactions reported in literature demonstrates a predominant association of the up-regulated 78 
proteins with glycolysis/gluconeogenesis, pentose phosphate pathway (PPP), pyruvate-malate cycle, 79 
and lipid metabolism and of down-regulated proteins with Krebs cycle, spliceosome and non-80 
homologous end joining. A metabolomic analysis on glycolysis, Krebs cycle and PPP confirmed the 81 
modulation of these pathways. Among the identified proteins, fatty acid synthase (FASN) and 82 
acetoacetyl-CoA transferase (ACAT2) were among the most highly up-regulated and were chosen for 83 
further analysis. Our data indicate that treatment of cells with cerulenin, a specific FASN inhibitor, or 84 
with atorvastatin, a specific inhibitor of the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase 85 
(HMGCR), an enzyme located downstream to ACAT2 in the metabolic pathway that produces 86 
isoprenoids and cholesterol, preferentially decrease cell viability of Panc1 CSCs compared to parental 87 
cells. All our findings constitute a significant advance in the comprehension of PDAC CSC biology 88 
and provide interesting potential targets for the therapeutic approaches to PDAC designed to 89 
specifically eliminate the CSC cellular component of the tumour.  90 
  91 
 
 
MATERIALS AND METHODS 92 
Cell culture  93 
The human PDAC cell line Panc1, called here Panc1 parental cells, was grown in RPMI 1640 94 
supplemented with 10% FBS, 2 mM glutamine, and 50 µg/ml gentamicin sulfate (Gibco, Life 95 
Technologies). Adherent cells were maintained in standard conditions for a few passages at 37°C with 96 
5% CO2. Panc1 CSCs were obtained as previously described [7]. Briefly, adherent cells were cultured 97 
in CSC medium (i.e. DMEM/F‑12, B27, fungizone, penicillin/streptomycin, heparin, epidermal 98 
growth factor and fibroblast growth factor) for at least 1‑3 weeks or until the appearance of 99 
tumourspheres, which were then cultured in CSC medium for at least three passages before initiating 100 
the experiments. 101 
 102 
Sample preparation   103 
Samples were prepared as previously described [9]. Briefly, Panc1 cells and Panc1 CSCs cell 104 
pellet was collected, lysed in 0.5 M TEAB (Sigma) and 0.1% SDS supplemented with protease 105 
inhibitor cocktail 1X (Roche), sonicated 3 times for 10 sec, stored at -80°C for 30 minutes and then 106 
sonicated again 3 times for 10 sec. Samples were then centrifuged at 14,000 x g for 10 min at 4°C to 107 
remove debris, and the supernatants were collected and stored and -80°C. Protein concentration was 108 
determined using BCA protein assay (Thermo Scientific).   109 
 110 
Protein digestion and iTRAQ labeling 111 
For this experiment, iTRAQ 8-plex reagents (Sciex, Framingham, USA) were used for the 112 
simultaneous analysis of the conditioned media [9] and whole cell lysates of Panc1 cells and Panc1 113 
CSCs. The samples labeled with 114, 116, 117, and 121 iTRAQ tags were used for the secretome 114 
analysis of and the data have already been published. In the present work were instead analyzed the 115 
samples labeled with 113, 115, 117, and 119 tags. In particular, one biological replica of Panc1 cell 116 
line and of Panc1 CSC whole cell lysates were labeled with iTRAQ reagent 113 and 115, respectively, 117 
 
 
and a second biological replicate (from a different cell culture passage) was labeled in the same order 118 
with iTRAQ reagents 117 and 119.  Protein digestion, iTRAQ labeling, and peptide fractionation and 119 
desalting were carried out as already described [9].  120 
 121 
LC-MS/MS analysis and data processing  122 
Desalted fractions were reconstituted in 40 L 0.1% formic acid and 5 L aliquots were 123 
delivered into a Triple TOF 5600 (Sciex) via an Eksigent NanoUltra cHiPLC System (Sciex) mounted 124 
with a microfluidic trap (200 µm x 500 µm ChromXP C18-CL 3 µm 300 Å) and analytical column (15 125 
cm × 75 μm) packed with ChromXP C18−CL 3 μm. A NanoSpray III source was fitted with a 10 μm 126 
inner diameter SilicaTip emitter (New Objective, Woburn, USA). The trap column was washed with 127 
2% ACN/0.1% formic acid for 10 min at 2 μL/min. A gradient of 2−50% ACN/0.1%  formic acid (v/v) 128 
over 90 min was applied at a flow rate of 300 nL/min. Spectra were acquired automatically in positive 129 
ion mode using information-dependent acquisition powered by Analyst TF 1.5.1 software (Sciex). Up 130 
to 25 MS/MS spectra were acquired per cycle (approximately 10 Hz) using a threshold of 100 counts 131 
per s and with dynamic exclusion for 12 s. The rolling collision energy was increased automatically by 132 
selecting the iTRAQ check box in Analyst, and manually by increasing the collision energy intercepts 133 
by 5. TOF-MS spectra were acquired for 250 ms (mass range 400−1650 Da) and MS/MS spectra for 134 
100 ms each (mass range 100−1400 Da). Mass spectrometer recalibration was performed at the start of 135 
every fifth sample using a β-galactosidase digest standard.  136 
Data analysis was performed using ProteinPilot software (Version 4.2, revision 1340, Sciex) 137 
using default settings and with bias and background correction applied. The data were searched against 138 
UniProt/SwissProt database (2013_2, total 30,309,316 entries, 40,464 human entries searched) using 139 
the Paragon algorithm (4.2.0.0, version 1304, Sciex). The mass tolerance for both precursor and 140 
fragment ions was 10ppm [10]. The variable modifications selected for the search were ‘biological 141 
modifications’ (probability-based modification search of 461 biological, chemical and artefactual 142 
modifications), while the fixed modifications were carbamidomethylation of cysteines, and iTRAQ 143 
 
 
modification of C-terminal lysine residues and peptide N-termini. A global FDR value of 1% was used 144 
based on the number of proteins identified before 1% of the identifications were derived from a match 145 
to the reverse database [11] (equating to an unused score of 1.09 and a confidence of 91.9%). 146 
Similarly, a global FDR cut-off of 1% was used as the criterion for acceptance of individual MS/MS 147 
spectra and in this case corresponded to a confidence of 93.8%.  148 
Ratios were calculated from the areas under the curve for each iTRAQ reporter ion selecting 149 
different denominators depending on the comparisons to be made. Mean ratios were calculated based 150 
on all occurrences (up to 7) of all peptides for which there was a peptide confidence of >15% and 151 
where the protein was confidently identified through other evidence. Where a single peptide was used 152 
for quantification, the peptide confidence cut-off was 95%. Where a single peptide was used for 153 
identification, the cut-off was 99%. The Paragon algorithm performs a Student t-test on the 154 
unweighted log ratios (for background corrected data) and reports the p-value: for a final error rate of 155 
5% and with 1157 proteins quantified, the Bonferroni correction suggests a significant p-value at 156 
0.0043. 157 
 158 
Bioinformatics analysis of identified proteins 159 
Known and predicted protein associations were analyzed and visualized with STRING version 160 
10 software (http://stringdb.org/). We retrieved interactions that were of at least high confidence (score 161 
0.7), based exclusively on experimental and database knowledge, while excluding all other prediction 162 
methods implemented in STRING (such as text-mining and co-expression). Additional white nodes 163 
and network depth were kept to the minimum value (1), in order to exclude as many false positive 164 
interactions as possible.  165 
Moreover, Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Redwood City, CA) was used 166 
to perform a comprehensive analysis of modulated proteins that characterized Panc1 CSCs. The IPA 167 
Core Analysis allowed to identifying the most significant networks, biological functions, perturbed 168 
canonical pathways as well as potential upstream regulators associated with this signature. The settings 169 
 
 
were as follows: i) Reference set: Ingenuity Knowledge Base; ii) Relationship to include: Direct and 170 
Indirect; iii) Filter Summary: Consider only molecules and/or relationships where (species = Human) 171 
AND (confidence = Experimentally Observed).  172 
The most important networks were calculated on the basis of the IPA score (>40) which take 173 
into account the number of focus proteins and the size of the network to approximate the relevance of 174 
the network to the original list of proteins. Proteins associated with canonical pathways were estimated 175 
as significant using Fisher’s exact test (p-value ≤ 0.01) to determine the probability that the association 176 
between identified proteins and a canonical pathway could be explained by chance alone.  177 
We also performed the IPA Upstream Regulator analysis to identify a putative cascade of 178 
upstream transcriptional regulators that can further explain the observed expression changes in Panc1 179 
CSCs. The upstream regulators were assumed as valid effectors of gene/protein expression if the 180 
corresponding p-value obtained by Fisher’s exact test was ≤ 0.01. Activation z-score algorithm was 181 
used to allow for prediction whether an upstream regulator is activated (z≥2) or inactivated (z≤-2) 182 
based on the direction of expressional change of the associated genes. 183 
 184 
Western Blot analysis 185 
Western Blot analysis was performed on two independent biological replicates of Panc1 and 186 
Panc1 CSCs to validate quantitative data obtained by MS, and on a biological replicate of Panc1 CSCs 187 
to verify the level of expression of FASN and of ACAT2 after inhibition of fatty acid synthesis and 188 
mevalonate pathways. 189 
Protein samples were diluted 1:1 with Laemmli’s sample buffer (62.5 mM Tris-HCl, pH 6.8, 190 
25% glycerol, 2% SDS, 0.01% Bromophenol Blue), heated for 5 min at 95°C and separated by 191 
SDS/polyacrylamide gel electrophoresis (PAGE) on 12% T acrylamide gels in Tris/glycine/SDS 192 
buffer. Proteins were then electroblotted onto polyvinilydene fluoride membranes (Bio-Rad, Hercules, 193 
CA) at 80 V for 1h and 30 min at 4°C. Amido Black staining was used to confirm equal protein 194 
loading in different lanes. Non-specific sites were blocked by incubating the membranes with 5% non-195 
 
 
fat dried milk and 0.05% Tween-20 (Sigma-Adrich) in Tris-buffered saline for 1h at room temperature. 196 
Membranes were incubated with the primary antibodies at the appropriate dilutions in 1% non-fat 197 
dried milk, 0.05% Tween-20 in Tris-buffered saline for 3 h at room temperature. Blots were then 198 
incubated 1h at room temperature with the appropriate horseradish peroxidase (HRP)-conjugated 199 
secondary antibody (see the Supplemental Table 1). The immunocomplexes were visualized by 200 
chemiluminescence using the Chemidoc MP imaging system (Bio-Rad Laboratories) and the intensity 201 
of the chemiluminescence response was measured by processing the image with Image Lab software 202 
(Bio-Rad). 203 
 204 
Metabolite extraction 205 
Metabolomic analyses on Panc1 cells and Panc1 CSCs were performed as previously reported 206 
[12]. Cells were prepared following the protocol published by Sana et al. [13], with minor 207 
modifications as previously reported [12]. The sample was resuspended by adding 0.15 ml of ice-cold 208 
ultra-pure water (18MΩ) to lyse cells. The tubes were plunged into dry ice or a circulating bath at -209 
25°C for 0.5 min and then into a water bath at 37°C for 0.5 min. To each tube was added 0.6 ml of -210 
20°C methanol and then 0.45 ml of -20°C chloroform. The tubes were mixed every 5 min for 30 min. 211 
Subsequently, 0.15 ml of ice-cold pH-adjusted ultra-pure water was added to each tube and these were 212 
centrifuged at 1000xg for 1 min at 4°C, before being transferred to -20°C for 2–8 h. After thawing, 213 
liquid phases were recovered and an equivalent volume of acetonitrile was added to precipitate any 214 
residual protein. The tubes were then transferred to a refrigerator (4°C) for 20 min, centrifuged at 215 
10,000xg for 10 min at 4°C and the collected supernatants were dried to obtain visible pellets. Finally, 216 
the dried samples were re-suspended in 1 ml of water, 5% formic acid and transferred to glass 217 
autosampler vials for LC/MS analysis.  218 
 219 
Rapid-resolution reverse-phase HPLC for metabolite separation 220 
 
 
An Ultimate 3000 Rapid Resolution HPLC system (DIONEX, Sunnyvale, USA) was used to perform 221 
metabolite separation. The system featured a binary pump and vacuum degasser, well-plate 222 
autosampler with a six-port micro-switching valve, and a thermostated column compartment. A 223 
Phenomenex Luna 3µm HILIC 200A (150 × 2.0 mm), protected by a guard column HILIC 4 × 2.0 mm 224 
ID (Phenomenex), was used to perform metabolite separation over a phase B to phase A gradient 225 
lasting 35 minutes. For the HILIC separation, a solution of 50 mM ammonium acetate was prepared by 226 
dissolving ammonium acetate in deionized water. Aqueous ammonium acetate was mixed with 227 
acetonitrile (95:5, v/v). This was used for the mobile phase ‘A’. The eluent ‘B’ was composed of a 228 
mixture of 50 mM aqueous ammonium acetate: water plus acetonitrile (95:5), v/v). Acetonitrile, 229 
formic acid, and HPLC-grade water and metabolite standards (≥ 98% chemical purity) were purchased 230 
from Sigma Aldrich. 231 
 232 
Mass spectrometry: Q-TOF settings 233 
Due to the use of linear ion counting for direct comparisons against naturally expected isotopic 234 
ratios, time-of-flight instruments are most often, being the best choice for molecular formula 235 
determination. Thus mass spectrometry analysis was carried out on an electrospray hybrid quadrupole 236 
time-of-flight instrument MicroTOF-Q (Bruker-Daltonik, Bremen, Germany) equipped with an ESI-237 
ion source. Mass spectra for metabolite-extracted samples were acquired  in negative ion modes. ESI 238 
capillary voltage was set at 4500 V (−) ion mode. The liquid nebulizer was set at 27 psi and the 239 
nitrogen drying gas was set to a flow rate of 6 L/min. Dry gas temperature was maintained at 200 °C. 240 
Data were stored in a centroid mode. Data were acquired with a stored mass range of 50–1200 m/z. 241 
Because calibration of the mass analyzer is essential in order to maintain a high level of mass 242 
accuracy, instrument calibration was performed externally every day with a sodium formate solution 243 
consisting of 10 mM sodium hydroxide in 50% isopropanol: water, 0.1% formic acid. Automated 244 
internal mass scale calibration was performed through direct automated injection of the calibration 245 
solution at the beginning and at the end of each run by a 6-port divert-valve.  246 
 
 
Metabolite data elaboration 247 
Replicates were exported as mzXML files and processed through MAVEN.52; mass 248 
spectrometry chromatograms were elaborated for peak alignment, matching and comparison of parent 249 
and fragment ions, and tentative metabolite identification (within a 10 ppm mass-deviation range 250 
between observed and expected results against the imported KEGG database).  MAVEN is an open-251 
source software that could be freely downloaded from the official project websites (http://genomics-252 
pubs.princeton.edu/mzroll/index.php?show=download).  Results were graphed with Graphpad Prism 253 
5.01 (Graphpad Software Inc). Statistical analyses were performed with the same software, as a result 254 
of paired t-test or two-way ANOVA among the results obtained from Panc1 and Panc1 CSCs. 255 
 256 
Cerulenin and atorvastatin treatments, cell proliferation assay and morphologic changes  257 
Cerulenin and atorvastain were obtained from Sigma-Aldrich St. Louis, MO. Cerulenin was 258 
dissolved in ethanol at a final concentration of 20 mg/ml and stored at -20°C. Atorvastatin was 259 
dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich) at a final concentration of 10 mg/ml and 260 
stored at room temperature. Panc1 and Panc1 CSCs (5×10
3
 cell/well) were cultured in 96-well plates 261 
and incubated at 37°C with 5% CO2. Twenty-four hours later, cells were treated with a serial 262 
concentration of cerulenin (0, 5, 10, 25, 50, 100, 250, and 500 µM) or of atorvastatin  (0, 2.5, 5, 10, 25, 263 
50, 100, and 250 µM). Three independent experiments were performed.  264 
After 48 h of each treatment, resazurin dye solution was added in an amount equal to 10% of 265 
the culture medium volume and plates were incubated for 1 h at 37°C with 5% CO2. Metabolic activity 266 
of living cells was measured fluorometrically by monitoring the increase in fluorescence at a 267 
wavelength of 590 nm, using an excitation wavelength of 535 nm on an automatic microplate reader. 268 
The effect of inhibitors on cellular morphology was assessed by collecting phase-contrast microscopy 269 
images of Panc1 and Panc1 CSCs cells after 48 h.  270 
 271 
Statistical analysis 272 
 
 
The data for inhibitors-treated cells and non-treated controls were compared using two-way 273 
analysis of variance (ANOVA) and Student’s t-test. P-values less than 0.05 were regarded statistically 274 
significant. All data were processed using GraphPad Prism Software Version 6.0 (La Jolla, CA, USA). 275 
 276 
 277 
RESULTS  278 
Differential profile of the whole cell proteome in Panc1 CSCs respect to Panc1 cells  279 
Protein expression profiles of Panc1 cells and Panc1 CSCs were investigated using the iTRAQ 280 
approach. A total of 2045 proteins with at least 93.8% confidence and an Unused ProteinPilot scores > 281 
1.09 (equating to a global FDR of 1%) were identified and among them 1157 proteins were quantified 282 
(Supplemental Table 2). Of these, 608 were identified via a single peptide with a confidence of 99% 283 
(Supplemental Table 3). Differential protein expression was considered to be significant when the 284 
expression increased or decreased with a fold change of 1.5 and a p value smaller than 0.05 in both 285 
biological replicates. A total of 230 proteins were found differentially expressed (Supplemental Table 286 
4) and among them 115 proteins were up-regulated and 115 down-regulated in Panc1 CSCs as 287 
compared to Panc1 parental cells. 288 
 289 
Interaction networks, pathway analyses, and upstream regulators of Panc1 CSC proteins 290 
STRING analysis emphasized that the majority of the differentially expressed Panc1 CSC 291 
proteins interact within established complexes or have functional relationships.  292 
The most striking pathways involving the proteins up-regulated in Panc1 CSCs compared to 293 
parental cells belong to carbon metabolism and are, in particular, glycolysis/gluconeogenesis, pyruvate 294 
metabolism, biosynthesis of amino acids, and pentose phosphate pathway (Fig. 1). On the contrary, the 295 
down-regulated proteins are mainly involved in the interactions with molecular components of the 296 
spliceosome and non-homologous end joining (Fig. 2).  297 
 
 
To reveal significant networks and biological functions relevant to Panc1 CSCs, we also 298 
performed an IPA. The up-regulated proteins show the highest-score for networks including cell death 299 
and survival, cellular assembly and organization, cell-to-cell signalling and interaction, cellular 300 
development, growth and proliferation, and carbohydrate metabolism, while the down-regulated 301 
proteins are involved in cell death and survival, cellular growth and proliferation, and RNA post-302 
transcriptional modification (Supplemental Fig 1).  Next, we systematically evaluated the biological 303 
functions of the identified proteins. Most of the regulated Panc1 CSC proteins appear to be involved in 304 
cancer, cellular growth and proliferation (Table 1). In particular, the up-regulated proteins are 305 
specifically involved in cellular movement and free radical scavenging, while the down-regulated 306 
proteins are specifically connected to the post-transcriptional modification of RNA and to cellular 307 
response to therapeutics. Overall, IPA software revealed that the Panc1 CSC modulated proteins show 308 
a significant link with 21 or 19 different pathways for up- or down-regulated proteins, respectively 309 
(Supplemental Table 5). The ten top canonical pathways (p-value ≤ 0.001) are shown in Figure 3. 310 
Among the most statistically significant canonical pathways, glycolysis (P-value: 7.94 E-11) and 311 
gluconeogenesis (P-value: 1.12 E-10) are included for the up-regulated proteins and DNA double-312 
strand break repair by non-homologous end joining (P-value: 1.23 E-06) and telomere extension by 313 
telomerase (P-value: 1.66 E-06) for the down-regulated proteins. 314 
Finally, the IPA software allowed us to examine also the potential upstream regulators 315 
associated with the above-described proteomic profiles. In particular, the upstream regulators predicted 316 
to be significantly activated include the transcription factors HIF1A (p = 1.29E-09, z = 2.228) and 317 
SMARCA4 (p = 5.36E-06, z = 2.219), as well as the estrogen-related receptor gamma ESRRG (p = 318 
4.24E-07, z = 2.180), while the transcription factor NR1H4 (p = 2.08E-05, z = -2.236) is predicted to 319 
be inhibited in Panc1 CSCs. A complete list of transcriptional upstream regulators with significant p-320 
values (p≤0.01) can be found in Supplemental Table 6. 321 
 322 
 323 
 
 
Western blot analyses of selected proteins identified by iTRAQ  324 
Seventeen differentially expressed proteins (ten up-regulated and seven down-regulated in 325 
Panc1 CSCs), for which commercial antibodies were available, were selected for validation using 326 
Western blot analyses. The expression level of proteins in Panc1 cells and Panc1 CSCs were compared 327 
on two biological replicates. As shown in Figure 4, Western blot results are consistent with the MS 328 
quantification data. Notably, in Panc1 CSCs relative to parental cells, MARCKS is up-regulated at 329 
intracellular level only as intact (~ 80 kDa), but not as cleaved (~ 40 kDa) form and more isoforms of 330 
Integrin beta-1 (ITGB1) and hnRNP A2/B1 (HNRNPA2B1) are immunodetected and all appear to be 331 
down-regulated. 332 
 333 
Metabolomic analysis of Panc1 CSCs  334 
  Since the proteomic analysis revealed that carbon metabolism (mainly glycolysis and pyruvate 335 
metabolism) is the pathway that characterizes the proteins induced in Panc1 CSCs (Fig. 1), we 336 
determined fold-change variations of the concentration levels of several key metabolites of glycolysis, 337 
Krebs cycle, and the energetic metabolism. Figure 5A shows that the glycolytic intermediates are 338 
mainly present at higher level in Panc1 CSCs in comparison to Panc1 parental cells. In particular, 339 
Panc1 CSCs show a significant increase in glucose-6 phosphate, fructose-1,6 bisphosphate, 340 
glyceraldehyde-3 phosphate, and lactate, while pyruvate decreases. We next investigated whether the 341 
accumulation of glycolytic intermediates was associated to an increase in refueling of pentose 342 
phosphate pathway (PPP). Interestingly, Panc1 CSCs reveal the accumulation of PPP intermediates, 343 
both of the oxidative phase (D-gluconic acid and D-ribose 5-phosphate) and non-oxidative phase 344 
(sedoheptulose 7-phosphate and D-xylulose phosphate) (Figure 5B). In line with the increased level of 345 
glycolysis metabolites, Krebs cycle intermediates including succinate, fumarate, and malate are 346 
decreased and two Krebs cycle-related metabolites, glutamine and glutamate, are decreased and 347 
increased, respectively, in Panc1 CSCs compared to Panc1 P cells (Figure 5C).  348 
 349 
 
 
Decreased cell viability of Panc1 CSCs in response to inhibition of fatty acid synthesis and 350 
mevalonate pathways 351 
The observation that FASN was expressed at 18 fold higher level in Panc1 CSCs compared to 352 
Panc1 cells led us to investigate the role of fatty acid synthesis in Panc1 CSC viability. For this 353 
purpose, we tested the effect of cerulenin, a specific FASN inhibitor, on the proliferative activity of 354 
Panc1 cells and Panc1 CSCs.  The cell viability assay was performed 24 (data not shown) or 48 hours 355 
after the beginning of the treatment with cerulenin at concentrations ranging from 0 to 500 μM. As 356 
shown in Figure 6A, cerulenin is able to decrease cell viability at a significantly higher level in Panc1 357 
CSCs compared to Panc1 cells with IC50 values of 15.6 µM  1.3 and 24.2 µM  1.7, respectively. 358 
This result strongly suggests an increased cell viability role of fatty acid synthesis in CSCs compared 359 
to parental cells. 360 
In a parallel experiment, conceived on the observation that ACAT2 was expressed at 21 fold 361 
higher level in Panc1 CSCs compared to Panc1 cells, we examined the role of isoprenoids/cholesterol 362 
synthesis in Panc1 CSC viability. For this purpose, we used the drug atorvastatin, which is known to 363 
specifically inhibit HMG-CoA reductase, an enzyme located downstream to ACAT2 in the metabolic 364 
pathway that produces isoprenoids and cholesterol. We cultured both Panc1 cells and Panc1 CSCs for 365 
24 (data not shown) and for 48 hour with atorvastatin at concentrations ranging from 0 to 250 μM. As 366 
shown in Figure 6B, atorvastatin strongly inhibits the viability of Panc1 CSCs, while only slightly 367 
reduces that of Panc1 cells, with IC50 values of 43 µM  24.8 and > 250 µM, respectively. This result 368 
strongly suggests an increased cell viability role of isoprenoids/cholesterol synthesis in CSCs 369 
compared to parental cells. 370 
To verify whether treatments with cerulenin and atorvastatin had an effect on the expression 371 
level of FASN and ACAT2 and to ascertain that the up-regulation of FASN observed in Panc1 CSCs 372 
was not a consequence of the presence of growth factors in the culture medium [14], a western blot 373 
analysis was performed. As shown in Figure 7, FASN level is independent of the presence of EGF and 374 
FGF in the culture medium and is not modulated by the treatment with the specific inhibitor cerulenin, 375 
 
 
which is a covalent inactivator of the β-ketoacyl synthase reaction on FAS. On the contrary, the 376 
expression level of ACAT2 in Panc1 CSCs appears to be increased after the inhibition of the 377 
mevalonate pathway by atorvastatin. 378 
 379 
Morphologic changes of Panc1 cells and Panc1 CSCs in response to the inhibition of fatty acid 380 
synthesis and mevalonate pathways 381 
To evaluate if the inhibition of fatty acid synthesis had an effect on cellular morphology, we examined 382 
cells by a phase-contrast microscope at 48 hours after treatment with 0, 25, 100 or 250 µM cerulenin. 383 
Before treatment, Panc1 cells exhibited a typical epithelial morphology with intact cell-to-cell 384 
contacts, while Panc1 CSCs exhibited a mesenchymal morphology with cell aggregates (or spheroids) 385 
and a more dispersed colony appearance suggesting an epithelial mesenchymal transition (EMT) 386 
phenotype. Interestingly, after cerulenin treatment, Panc1 cells exhibited only a decreased cell-to-cell 387 
contact, while Panc1 CSCs showed drastic changes in cell morphology, with reduction of spheroids 388 
suggesting cytoskeletal reorganization (Fig. 8A). The analysis also indicated that the anti-389 
proliferative/viability effect was due, at least in part, to the decrease in cell number after cerulenin 390 
treatment.  391 
We also evaluated the effect of atorvastatin on the morphology of Panc1 cells and Panc1 CSCs. 392 
As shown in Figure 8B, the effect on cell morphology of this inhibitor was similar to that of cerulenin. 393 
Phase-contrast microscopy images show in fact that after atorvastatin treatment Panc1 CSCs were 394 
characterized by a reduction of spheroids suggesting cytoskeletal reorganization, while Panc1 cells 395 
exhibited a decrease in cell-to-cell contacts. In addition, Panc1 CSCs were rounded and detached after 396 
atorvastatin treatment. 397 
 398 
 399 
 400 
 401 
 
 
DISCUSSION 402 
Activated metabolic pathways in Panc1 CSCs 403 
Our previous study [9] showed higher secretion level of different proteins in Panc1 CSCs compared 404 
with the parental cells, and hence suggested possible involvement of these proteins in the processes of 405 
pancreatic cancer differentiation, invasion, and metastasis.  406 
 In the present study, with the aim of further deepening the understanding of pancreatic CSC 407 
biology, we carried out a proteomic analysis of Panc1 and Panc1 CSC whole-cell extracts to 408 
investigate the intracellular molecular mechanisms characterizing pancreatic CSCs. The data obtained 409 
revealed the regulation of some key metabolic pathways in Panc1 CSCs (Fig. 9).  410 
Our proteomic results indicate that glycolysis and gluconeogenesis (Fig.1 and Fig. 3), 411 
previously reported to be involved in the secretome of both Panc1 cells and Panc1 CSCs [9], are also 412 
strongly represented by intracellular up-regulated proteins in Panc1 CSCs. In particular, data show that 413 
fructose-bisphosphate aldolase A (ALDOA, +15.31), triosephosphate isomerase (TPI1, +13.25), 414 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, +9.21), phosphoglycerate kinase 1 (PGK1, 415 
+2.37), phosphoglucomutase-1 (PGM1, +18.29), phosphoglycerate mutase 1 (PGAM1, +12.26), alpha-416 
enolase (ENOA, +13.48), and pyruvate kinase isozymes M1/M2 (PKM, +18.76) are all more highly 417 
expressed in Panc1 CSCs than in the parental cells. Furthermore, Panc1 CSCs also express an 418 
increased level of both L-lactate dehydrogenase A and B chains (LDHA +10.12, LDHB +15.13), 419 
which indicates an accentuation of the Warburg effect. According to these data, the upstream regulator 420 
analysis performed in silico by IPA has identified, among other activated regulators, the transcription 421 
factor HIF1A. Indeed, HIF1α, which is typically up-regulated even in solid malignancies in normoxia, 422 
modulates stem cell fate reprogramming through glycolytic shift and upregulation of PKM2 [15, 16]. 423 
Notably, it has also been demonstrated that HIF1A promotes pancreatic ductal adenocarcinoma 424 
invasion and metastasis by activating transcription of the actin-bundling protein fascin [17]. In line 425 
with this finding, we found that fascin is up-regulated 7.06 fold in Panc1 CSCs as compared to 426 
parental cell line (see Suppl. Table 4).  427 
 
 
 In agreement with the increased expression of glycolytic enzymes, our metabolomic data show 428 
that in CSCs the level of glucose-6 phosphate is enhanced, suggesting an increased activity of 429 
exokinase in CSCs, despite its expression not differing between cell lines, as shown by the proteomic 430 
data. The other glycolytic intermediates that were analysed were present at higher levels in CSC 431 
compared to parental cells, though the 2-phopshoglycerate level was not significantly different, 432 
confirming a more glycolytic metabolism for CSCs. In line with this observation and with the 433 
proteomic data, the level of lactate is also significantly higher in CSCs than in parental cells. 434 
The recent literature describes CSCs as being primarily glycolytic or preferentially relying on 435 
oxidative phosphorylation depending on tumour-type and microenvironment [18]. However, it has 436 
been shown that in glucose rich environments, proliferating CSCs primarily utilize aerobic glycolysis 437 
for their bioenergetic needs, while in glucose (and oxygen) deprived conditions, CSCs shift to a 438 
quiescent, slow cycling state relying on mitochondrial oxidative metabolism [19]. In particular, the 439 
activation of the glycolytic programme favours stemness via various mechanisms [20, 21], including 440 
enhanced antioxidative capacity, with pentose phosphate pathway (PPP) being the most relevant. Our 441 
results indicate that several up-regulated proteins of Panc1 CSCs belong to “free radical scavenging” 442 
among top biological functions (Table 1) and to PPP as a statically significant perturbed pathway (Fig. 443 
1 and Fig. 3). Among PPP enzymes, Panc1 CSCs show over-expression of glucose-6-phosphate 1-444 
dehydrogenase (G6PD, +5.61), 6-phosphogluconate dehydrogenase (PGD, +11.67), and transketolase 445 
(TKT, +5.66). These results are also confirmed by  the  metabolomic  analysis  which  highlights  the 446 
increase  of  PPP  intermediates  (Fig. 9). The PPP is a major glucose metabolic pathway required for 447 
cellular demands of anabolism and antioxidant defence. Indeed, the main purpose of PPP is to 448 
regenerate NADPH from NADP+ through an oxidation/reduction reaction. This reaction is coupled to 449 
the formation of ribose 5-phosphate from glucose 6-phosphate, thus making PPP among the major 450 
metabolic pathways involved in malignancies [22]. Our data show increase of metabolic intermediates 451 
and byproducts especially of the oxidative phase of PPP (D-gluconic acid and D-ribose 5-phosphate).  452 
The increase of oxidative phase intermediates might be explained through diversion to purine salvage 453 
 
 
pathway (PSP), as observed in red blood cell [23]. Purine nucleotides may be synthesized in cells de 454 
novo or reconstructed from already existing free purine bases through the salvage reactions 455 
(reutilization) [23].  456 
In Panc1 CSCs, in line with the up-regulation of enzymes involved in glycolysis and PPP, we 457 
also observed an induction of enzymes involved in the pyruvate-malate cycle (citrate-pyruvate cycle) 458 
(Fig.1 and Fig. 3), i.e. the cytosolic ATP-citrate synthase (ACLY, +2.77), cytoplasmic malate 459 
dehydrogenase (MDH1, +10.17) and cytosolic NADP-dependent malic enzyme (ME1, +12.19). This 460 
pathway is responsible for citrate transport out of the mitochondria into the cytosol where it is cleaved 461 
by ACLY to oxaloacetate and acetyl-CoA, which is available for fatty acid synthesis. On the other 462 
hand, cytosolic oxaloacetate is hydrogenated by MDH1 to give NAD
+
 and malate, which is then 463 
oxidized by ME1 to pyruvate in a reaction which also provides NADPH mainly for fatty acid 464 
synthesis. Thus, NADH generated in glycolysis is converted to NADPH for fatty acids synthesis, while 465 
simultaneously regenerating the NAD
+
 needed to continue glycolysis [24]. Recently, it has been 466 
reported that PDAC cells rely on the pyruvate-malate cycle to increase the NADPH/NADP (+) ratio, 467 
and that oxaloacetate is produced by a metabolic reprogramming mediated by the KRAS oncogene 468 
[25]. Accordingly, we demonstrate that Panc1 cells, which are known to possess a KRAS mutation 469 
[26], express enzymes of the pyruvate-malate cycle and that these enzymes are even more expressed in 470 
Panc1 CSCs.  471 
Consistently with the up-regulation of enzymes involved in glycolysis, PPP, and pyruvate-472 
malate cycle, we also found that Panc1 CSCs have a strong induction of two cytosolic enzymes 473 
involved in lipid metabolism, the cytosolic acetylCoA acetyl transferase (ACAT2, +21.19 fold), which 474 
synthesize acetoacetylCoA in the mevalonate pathway leading to cholesterol, and the fatty acid 475 
synthase (FASN, +18.36 fold), which synthesize fatty acids.  476 
Recently, in proliferating cells, it has been demonstrated that NADPH production, beyond the 477 
important contribution of PPP and the malic enzyme (ME1), originates from the serine-driven one-478 
carbon metabolism, in which oxidation of methylene tetrahydrofolate to 10-formyl-tetrahydrofolate is 479 
 
 
catalysed by the methylene tetrahydrofolate dehydrogenase (MTHFD) with the reduction of NADP to 480 
NADPH [27].  Our data demonstrate for the first time that Panc1 CSCs are characterized by increased 481 
levels of the cytosolic MTHFD1 (+3.19) compared to parental cells suggesting that stemness requires a 482 
higher contribution of the folate pathway for NADPH homeostasis.  483 
 484 
Repressed pathways in Panc1 CSCs 485 
As a further confirmation of a switch to a glycolytic metabolism at the expense of the 486 
mitochondrial oxidative metabolism, Panc1 CSCs also show a down-regulation of some key enzymes 487 
of the Krebs cycle (Supplemental Table 4). In support of these results, the metabolomic data show 488 
that the level of three Krebs cycle intermediates, i.e. succinate, fumarate, and malate, is significantly 489 
decreased in CSCs in comparison to parental cells (Fig. 5B). Furthermore, glutamine level is decreased 490 
in CSCs compared to P cells, suggesting either a less active glutamine-transport inside the cell or a 491 
greater conversion of glutamine to glutamate. Indeed, glutamate level is enhanced in CSCs compared 492 
to parental cells, suggesting a minor incorporation of glutamate in the mitochondrion and, together 493 
with the other results, a less active Krebs cycle in CSCs in comparison to parental cells.  494 
In Panc1 CSCs, proteins involved in spliceosome formation and non-homologous end joining 495 
pathway appear to be down-regulated compared to Panc1 cells (Fig.2 and Fig.3), in particular, several 496 
hnRNPs (A1, A3, A/B, A2/B1, C1/C2, H3, K, L, M,  U, Q), two splicing factors (3B subunit 2, 1 497 
serine/arginine-rich), and the RNA-binding protein 25. The down-regulation of multiple types of 498 
hnRNPs may represent a strategy of stem cells to keep their undifferentiated state. Indeed, it has been 499 
demonstrated that hnRNPs play a key role in the stem cell differentiation process, as for example in the 500 
case of embryonic stem cells differentiated into smooth muscle cell, or of multipotent hematopoietic 501 
stem cells differentiated into the different types of blood cell, or of neural stem cell differentiated into 502 
neuronal cells [28].  503 
The non-homologous end-joining (NHEJ) pathway is one of the main mechanisms for repairing 504 
breaks in double-stranded DNA. In Panc1 CSCs, representative proteins of this pathway (Fig.2 and 505 
 
 
Fig.3), i.e. poly [ADP-ribose] polymerase 1 (PARP1, -1.96), DNA-dependent protein kinase catalytic 506 
subunit (PRKDC, -2.27), and X-ray repair cross-complementing proteins 5 and 6 (XRCC5 -1.89, 507 
XRCC6 -1.92), are down-regulated. Interestingly, PARP1 is a pro-apoptotic enzyme [29], the 508 
expression of which has been shown to be specifically reduced in stem cells with spherical 509 
morphology as compared to monolayer cells [30]. Furthermore, XRCC5 and XRCC6 encode for Ku80 510 
and Ku70 proteins, which form the Ku heterodimer that is involved in repairing double-strand breaks 511 
in DNA for maintaining the integrity of genome function. Either Ku70 or Ku80 themselves have also 512 
unique functions that are independent of the other Ku subunit [31], as for instance the tumour 513 
suppressor activity of Ku70 [32]. In particular, it has been reported that colonic epithelial cells of mice 514 
with Ku70 deficiency and p53
R172P
 mutation (Ku70
−/−
PP) show higher rates of proliferation and 515 
induction of -catenin/Wnt pathway, which is important in promoting EMT. Notably, our previous 516 
data demonstrated that Panc1 CSCs express higher levels of typical EMT markers compared to 517 
parental cells [7].  518 
 519 
Functional role of fatty acid synthesis and mevalonate pathways in Panc1 CSC viability 520 
Among the most strongly induced proteins of Panc1 CSCs, we found of particular interest 521 
FASN and ACAT2 that, as mentioned above, are involved in lipid metabolic pathways. Notably, high 522 
expression level of FASN has been linked to a significantly poor prognosis of PDAC patients and it 523 
has been shown to depend upon the induction of EGFR/ERK signalling [14]. Furthermore, FASN has 524 
been shown to promote EMT in many cancers, including ovarian [33], breast [34] and colorectal [35] 525 
cancer. Our results demonstrate that the overexpression of FASN in Panc1 CSCs is independent of the 526 
presence of EGF and FGF in the medium, suggesting a constitutive activation of the EGFR/ERK 527 
pathway.   528 
Inhibition of FASN is known to selectively target cancer cells for apoptosis, mainly by 529 
interfering with membrane function, inhibiting DNA replication and anti-apoptotic proteins, and 530 
accumulating the malonyl-Co-A substrate [36]. Cerulenin is a natural FASN inhibitor that binds 531 
 
 
specifically and irreversibly to the -ketoacyl synthase domain of FASN, thus preventing the 532 
condensation reaction between the elongating fatty acid and successive malonyl residues. Interestingly, 533 
our results show that cerulenin inhibits Panc1 and Panc1 CSC proliferation, with a greater anticancer 534 
activity on stem cells (Fig.6A). This is a new observation that could open novel lines of investigation 535 
for the development of PDAC CSC target specific therapeutic strategies.  536 
The other metabolic pathway that caught our attention was the mevalonate pathway, which is 537 
involved in cholesterol production, because of the strong up-regulation in Panc1 CSCs of ACAT2, one 538 
of its key enzymes. The mevalonate pathway affects cancer metastasis in several ways by influencing 539 
EMT, cytoskeleton remodelling, as well as cell motility and polarity (non-canonical Wnt/planar 540 
pathway). Statins are competitive inhibitors of this pathway by acting on the enzyme the 3-hydroxy-3-541 
methyl-glutaryl-coenzyme A reductase (HMGCR) and blocking the conversion of HMG-CoA to 542 
mevalonate. The statins occupy the catalytic site of HMGCR at the level of the binding site for HMG-543 
CoA, thus blocking the access of this substrate to the active site. In the last two decades, the successful 544 
and widespread uses of statin drugs for hypercholesterolaemia have revealed their potential anticancer 545 
effects demonstrating that the use of statins is associated with reduced cancer-related mortality [37].  546 
Inhibition of mevalonate pathway by statins has shown to have an antitumour effect against certain 547 
CSCs, but their effects have never been investigated on pancreatic CSCs [38]. Our data demonstrate 548 
that atorvastatin, a synthetic statin, inhibits cell growth of both Panc1 cells and Panc1 CSCs and that 549 
CSCs are considerably more sensitive than parental cells (Fig.6B), suggesting ACAT2 as a potential 550 
target for PDAC CSC specific therapy. In conclusion, the different cytotoxic effects by inhibiting fatty 551 
acid synthesis and mevalonate pathways on Panc1 and Panc1 CSCs suggest that the acute reduction of 552 
fatty acids or cholesterol production per se are not the major source of cell injury, but could target 553 
specific stemness characteristics.  554 
In summary, the proteomic and metabolomic analysis on Panc1 cells and Panc1 CSCs 555 
highlighted the main metabolic routes used by pancreatic cancer stem cells to survive, proliferate and 556 
disseminate in distinct healthy tissues. In particular, these data indicate that the maintenance of high 557 
 
 
fatty acid synthesis and mevalonate pathway levels could make critical contribution to survival of 558 
pancreatic cancer stem cells. Although targeting tumour metabolism is still in the early days of 559 
translation to patients, the improvement on knowledge of deranged metabolic pathways, in particular 560 
in cancer stem cells, will accelerate the development of novel therapeutic strategies. 561 
 562 
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Figure Legends  659 
Figure 1 660 
Protein network of up-regulated proteins of Panc1 CSCs.  661 
Schematic view of known and predicted protein interactions according to the STRING database (v. 662 
10). Each node represents a protein, and each edge represents an interaction. Only interactions with the 663 
highest confidence score (0.700) are shown. Interactions include physical and functional associations, 664 
showing the evidence view. Thicker edges represent stronger associations. 665 
 666 
Figure 2 667 
Protein network of down-regulated proteins of Panc1 CSCs.  668 
Schematic view of known and predicted protein interactions according to the STRING database (v. 669 
10). Each node represents a protein, and each edge represents an interaction. Only interactions with the 670 
highest confidence score (0.700) are shown. Interactions include physical and functional associations, 671 
showing the evidence view. Thicker edges represent stronger associations. 672 
 673 
Figure 3 674 
IPA Canonical Pathways analysis.  675 
The top 10 significantly altered canonical pathways associated with up-regulated (upper panel) and 676 
down-regulated (lower panel) proteins of Panc1 CSCs. The y-axis indicates the statistical significance 677 
calculated using the right-tailed Fisher exact test and the p value indicates the probability of 678 
association of proteins with the canonical pathway by random chance alone. Thus, taller bars equate to 679 
increased significance. The threshold line represents the default significance cut-off at p = 0.05. The 680 
ratio is calculated as follows: the number of molecules found in a given pathway divided by total 681 
number of molecules that constitute that specific canonical pathway. 682 
 
 
The orange and blue coloured bars indicate predicted pathway activation, or predicted inhibition, 683 
respectively (z-score). White bars are those with a z-score at or very close to 0. Grey bars indicate 684 
pathways where no prediction can currently be made.   685 
 686 
Figure 4 687 
Western Blotting validation.  688 
Differential expression of Panc1 CSC up-regulated (A) and down-regulated (B) proteins was verified 689 
in two biological replicates (1 and 2).  Proteins were resolved in 10-20% SDS-PAGE gels, transferred 690 
onto PVDF membranes, and probed with specific antibodies against the indicated targets. Amido 691 
Black staining was used as total loading control.  692 
 693 
Figure 5 694 
Metabolites analysis. 695 
Absolute metabolomics quantification (arbitrary ion counts) of metabolites from glycolysis (A) 696 
Pentose phosphate pathway (B) and Krebs cycle (C) in Panc1 parental cells (P; white histogram) and 697 
Panc1 CSCs (black histogram). Values are presented as mean ± SD. The data were analyzed using 698 
Student’s t-test: * P< 0.05, ** P<0.01, and *** P<0.001 in Panc1 CSCs versus Panc1 P cells. 699 
 700 
Figure 6 701 
Anticancer effects of fatty acid and mevalonate pathways inhibition.   702 
Cerulenin and atorvastatin effectively inhibited Panc1 CSCs viability. (A) Comparison of cerulenin 703 
effects on Panc1 and Panc1 CSC cells viability. Cells were treated for 48 hours at doses ranging from 704 
0 to 500 μM. (B) Evaluation of atorvastatin effects on Panc1 and Panc1 CSC cells viability. Cells were 705 
treated for 48 hours at doses ranging from 0 to 250 μM. The data were analyzed using Student’s t-test. 706 
* P, 0.05. 707 
 708 
 
 
Figure 7 709 
Western Blotting analysis of Panc1 CSCs.   710 
(A) FASN protein levels in Panc1 CSCs control (CTRL) and treated with cerulenin, and grown 711 
without EGF and FGF (- EGF/FGF). (B) ACAT2 protein levels in Panc1 CSCs control (CTRL) and 712 
treated atorvastatin. Proteins were resolved in 10-20% SDS-PAGE gels, transferred onto PVDF 713 
membranes, and probed with specific antibodies against the indicated targets. Amido Black staining 714 
was used as total loading control.  715 
 716 
Figure 8 717 
Cellular morphology after inhibition of fatty acid synthesis and mevalonate pathways.  718 
Phase-contrast microscopy images of Panc1 and Panc1 CSCs after 24 hour of cerulenin (A) and 719 
atorvastatin (B) treatments.  720 
 721 
Figure 9 722 
Overview of key metabolic pathways in Panc1 CSCs. The up- and down-regulated proteins (enzymes) 723 
and metabolites identified in Panc1 CSCs compared to Panc1 P and mentioned into the discussion are 724 
shown in bold red and green, respectively. Proteins and metabolites that were not identified in this 725 
work are shown in gray. The inhibitors are shown in light blue. 726 
 727 
  728 
 
 
Table 1. IPA-predicted top biological functions for up-regulated and down-regulated proteins of Panc1 729 
CSCs. 730 
 731 
 
Top Biological Functions 
(Panc1 CSCs up-regulated proteins) 
P values
a 
(ranging from) 
No. of 
molecules
b
 
Diseases and Disorders   
Dermatological Diseases and Conditions 1.21E-02 - 1.05E-10 34 
Neurological Disease 1.21E-02 - 9.23E-09 49 
Skeletal and Muscular Disorders 1.16E-02 - 9.23E-09 50 
Psychological Disorders 1.21E-02 - 9.54E-09 34 
Cancer 1.25E-02 - 3.13E-08 102 
Molecular and Cellular Functions   
Cellular Growth and Proliferation 1.21E-02 - 1.17E-15 58 
Cell Death and Survival 1.21E-02 - 1.80E-11 52 
Cellular Development 1.21E-02 - 8.62E-08 34 
Cellular Movement 1.24E-02 - 1.22E-06 30 
Free Radical Scavenging 1.08E-02 - 1.50E-06 12 
Physiological System Development and Function   
Cell-mediated Immune Response 1.21E-02 - 3.47E-05 4 
Hematological System Development and Function 1.21E-02 - 3.47E-05 14 
Immune Cell Trafficking 1.21E-02 - 3.47E-05 10 
Endocrine System Development and Function 1.21E-02 - 5.40E-04 4 
Organismal Survival 7.10E-04 - 7.10E-04 9 
   
Top Biological Functions 
(Panc1 CSCs down-regulated proteins) 
P values
a 
(ranging from) 
No. of 
molecules
b
 
Diseases and Disorders   
Infectious Diseases 6.07E-03 - 2.85E-08 33 
Dermatological Diseases and Conditions 6.07E-03 - 1.14E-07 22 
Cancer 6.07E-03 - 2.15E-07 105 
Organismal Injury and Abnormalities 6.07E-03 - 2.15E-07 105 
Neurological Disease 6.07E-03 - 6.74E-07 42 
Molecular and Cellular Functions   
Cellular Growth and Proliferation 6.07E-03 - 1.56E-18 64 
RNA Post-Transcriptional Modification 6.07E-03 - 2.22E-17 23 
Cell Death and Survival 6.07E-03 - 2.24E-15 54 
Cellular Development 6.07E-03 - 8.12E-10 55 
Cellular Response to Therapeutics 1.00E-03 - 1.48E-09 7 
Physiological System Development and Function   
Skeletal and Muscular System Development and Function 1.09E-04 - 8.12E-10 12 
Tissue Development 6.07E-03 - 8.12E-10 30 
Cardiovascular System Development and Function 6.07E-03 - 3.70E-07 18 
Organismal Development 6.07E-03 - 3.70E-07 21 
Hair and Skin Development and Function 6.07E-03 - 2.03E-05 11 
 732 
a
 Fisher’s exact test was used to calculate a p value for each protein of the dataset identified in the biological function studied, indicating the probability 733 
that each biological function assigned to the data set is assigned by chance; then we have a range of p values corresponding to all p values calculated for 734 
all proteins of the dataset in the biological function. 
b 
The number of molecules of the differentially expressed protein dataset is shown. 735 
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